James Carroll’s Congress speech on ending opioid use with Photobiomodulation

A hundred million adults in the United States are affected by chronic pain and $600 billion a year is spent on in health care, direct health care costs and lost productivity because of pain.

49,000 people from opioids in 2017, 19,000 of which were from prescribed opioids for pain relief.

We believe that Photobiomodulation therapy can help reduce the prescribing of opioid medication for pain relief and we wish to draw attention to the Congress and health care policymakers, NIH and CMS, about this potentially valuable tool.

Learn more at CongressPBM.com

Read James Carroll’s Speech to Congress on citizenoversight.blogspot.com

View current photobiomodulation therapy training dates in your location.

More NovoTHOR Testimonials

Posted in Industry, THE FUTURE OF LLLT, Video of the Week | Leave a comment

NovoTHOR testimonial: Lyme Disease – Nadia’s Story

Nadia talks about how the NovoTHOR pod at Performance Bodywork in Portland, Oregon helps with healing, recovery and sustainability for her Lyme Disease.

View current photobiomodulation therapy training dates in your location.

More NovoTHOR Testimonials

Posted in Testimonials, Video of the Week | Leave a comment

Course Testimonial: Jan Kielmann

Jan Kielmann, Natural Health, LLC / Functional Wellness“I loved the workshop. In terms of science, integrity and authenticity it was the best laser workshop so far. I am blown away by the options PBM provides in helping our patients get better. So many people are moving from practitioner to practitioner without ever finding relief, especially in the field of fibromyalgia, chronic lyme disease and mitochondrial damage. Now we finally have something to offer that will hopefully help make dramatic changes possible.

Thanks for all you do and keep on pushing the boundaries! :-)”

Jan Kielmann
Natural Health, LLC / Functional Wellness
Southern California, USA

View current photobiomodulation therapy training dates in your location.

Posted in Testimonials | Leave a comment

NovoTHOR testimonial: Severe Rheumatoid Arthritis – Therese’s Story

Therese talks about how the NovoTHOR at Performance Bodywork in Portland, Oregon has been a huge help for her severe Rheumatoid Arthritis.

View current photobiomodulation therapy training dates in your location.

More NovoTHOR Testimonials

Posted in Testimonials, Video of the Week | Leave a comment

NovoTHOR testimonial about fibromyalgia: Ann Busby

Ann Busby had lived most of her adult life in pain. Ann was diagnosed with fibromyalgia back in 2001. She has been using the NovoTHOR off and on for over a year and says the changes in her body have been incredible.

View current photobiomodulation therapy training dates in your location.

More NovoTHOR Testimonials

Posted in Testimonials, Video of the Week | Leave a comment

NovoTHOR testimonial: Susan Julian

Susan Julian has had Lyme Disease for over 22 years. She talks about her transformation using the NovoTHOR bed at Infinity Healing.

View current photobiomodulation therapy training dates in your location.

More NovoTHOR Testimonials

Posted in Testimonials, Video of the Week | Leave a comment

LumiThera Receives Notice of Award for $2.5 Million National Eye Institute Grant to Support U.S. Multi-Center Clinical Trial for Treating Dry Age-Related Macular Degeneration

LumiThera Inc., a commercial stage medical device company creating a photobiomodulation (PBM) treatment for ocular disorders and disease, today announced it is a recipient of a small business innovative research (SBIR) phase II grant from the National Institute of Health (NIH) and the division of the National Eye Institute (NEI).

Valeda™ Light Delivery System patient treatmentThe phase II grant supports a prospective, randomized, multi-center human clinical trial in U.S. subjects diagnosed with dry age-related macular degeneration (dry AMD.) The LIGHTSITE III trial, which is subject to FDA Investigational Device Exemption (IDE) approval, will test vision and examine disease pathology in the eye following PBM treatments using the Company’s Valeda™ Light Delivery System. Subjects will be followed for up to two years. In 2018, LumiThera obtained a CE mark to commercialize the Valeda™ Light Delivery System in Europe for the treatment of dry AMD. A companion post-marketing study (LIGHTSITE II) is being readied for Europe.

“Dry AMD is one of the largest unmet medical needs in medicine and its prevalence is increasing as we live longer,” commented Quan Dong Nguyen, M.D., M.Sc. and Diana V. Do, M.D., both professors of ophthalmology at the Byers Eye Institute, Stanford University School of Medicine. “In ophthalmology, currently, we have no therapies that can be offered to these patients. Both of us and many of our colleagues at Stanford, in the US, and throughout the world recognize the potential that PBM could provide as an early treatment for dry AMD, and if so, can bring significant benefits to millions of patients globally.”

“The LIGHTSITE II and III trials are part of LumiThera’s global efforts to bring forward a treatment for a debilitating eye disease that results in central loss of vision,” stated David Boyer, MD., Retina-Vitreous Associates Medical Group, Los Angeles, CA. “The planned European and US trials would create a novel treatment option for dry AMD patients, who currently have limited choices.”

“The NIH clinical grant is substantial in providing over $2.5M in funding to develop a PBM therapy for dry AMD patients in the U.S.,” stated Clark Tedford, Ph.D., President and CEO. “We are excited to have the NIH/NEI partially support the further development endeavors of LumiThera, and the grant is a significant step in the validation of the PBM technology and its potential in treating chronic eye disease.”

“We are very excited to be part of the LIGHTSITE U.S. multicenter trial.” remarked Richard Rosen, M.D., New York Eye and Ear Infirmary of Mount Sinai. “Several major U.S. centers are participating in this trial, which should help substantiate the clinical benefits of this therapy, reported to date. This trial will measure a variety of clinical and pathological outcomes and establish the long-term benefits of PBM for dry AMD patients.”

View the press release on Lumithera website at www.lumithera.com

Disclosure: I am an investor in Lumithera a) because it successfully treats an unmet medical need, (dry AMD) b) I think it will be the first billion dollar photobiomodulation company.

Posted in Industry | Leave a comment